RCT: Among children between the ages of 6 and 11 years with uncontrolled moderate-to-severe asthma, add-on Dupilumab reduced exacerbations and improved lung function.
9 Dec, 2021 | 10:21h | UTCDupilumab in Children with Uncontrolled Moderate-to-Severe Asthma – New England Journal of Medicine